Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 729 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Inflammatory Response Syndrome (SIRS) Clear all
Terminated Phase 2 Interventional

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

NCT04540120
View directory record Official record
Conditions
Covid19, Cytokine Release Syndrome
Interventions
dapansutrile capsules, placebo capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 5, 2026, 5:55 PM EDT
Completed No phase listed Observational

HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study

NCT03744741
View directory record Official record
Conditions
Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections, Sepsis
Interventions
HostDx Sepsis
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Lexington, Kentucky • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 5, 2026, 5:55 PM EDT
Completed No phase listed Observational

VENUS: Septic Gene Expression Using SeptiCyte

NCT02127502
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
Interventions
Not listed
Lead sponsor
Immunexpress
Industry
Eligibility
18 Years to 89 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 3 Interventional

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288
View directory record Official record
Conditions
Candidiasis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis

NCT01739361
View directory record Official record
Conditions
Severe Sepsis
Interventions
Acetaminophen, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 5, 2026, 5:55 PM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

NCT01689441
View directory record Official record
Conditions
Severe Sepsis or Septic Shock
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 5, 2026, 5:55 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 5:55 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Midodrine Use in Septic Shock

NCT03706053
View directory record Official record
Conditions
Septic Shock
Interventions
Midodrine Hydrochloride, placebo
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 5, 2026, 5:55 PM EDT
Terminated No phase listed Observational

Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis

NCT00698542
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 5, 2026, 5:55 PM EDT
Not yet recruiting No phase listed Observational

Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool

NCT05311046
View directory record Official record
Conditions
Sepsis
Interventions
Pediatric sepsis screening tool (either algorithmic or manual)
Diagnostic Test
Lead sponsor
Computer Technology Associates, Inc.
Industry
Eligibility
3 Months to 45 Years
Enrollment
12,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 5, 2026, 5:55 PM EDT
Completed No phase listed Observational

Point of Care Ultrasound to Predict Intensive Care Unit Admission of Patients Presenting With Sepsis to the Emergency Department

NCT05544903
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:55 PM EDT
Completed No phase listed Observational

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

NCT02719769
View directory record Official record
Conditions
Bacteremia, Fungemia
Interventions
Not listed
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
4,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

The Effects of HIV Protease Inhibitors in Severe Sepsis

NCT00346580
View directory record Official record
Conditions
Sepsis
Interventions
Nelfinavir
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 5, 2026, 5:55 PM EDT
Not listed No phase listed Observational

CV-SQuISH-ED: Clinical Validation Study

NCT04933760
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Cytovale IntellipSep test
Diagnostic Test
Lead sponsor
Cytovale, Inc.
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Columbia, Missouri • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Lipid Infusion in Dialysis Patients With Endotoxemia

NCT00506454
View directory record Official record
Conditions
Fatigue, End Stage Renal Disease (ESRD)
Interventions
Lipidose, Placebo
Drug
Lead sponsor
Sepsicure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 5, 2026, 5:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

NCT02508649
View directory record Official record
Conditions
Septic Shock
Interventions
selepressin, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 5, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 5, 2026, 5:55 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 5, 2026, 5:55 PM EDT
Active, not recruiting No phase listed Observational

Measuring Outcomes of Activity in Intensive Care

NCT03115840
View directory record Official record
Conditions
Critical Illness, Sepsis, Mechanical Ventilation, Physical Activity, Disability Physical, Muscle Weakness, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 5, 2026, 5:55 PM EDT
Completed No phase listed Observational

Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis

NCT03055455
View directory record Official record
Conditions
Septic Shock
Interventions
MR imaging
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 5, 2026, 5:55 PM EDT